Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07153796 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-cell Acute Lymphoblastic Leukemia
A Phase 2 study of B-cell Acute Lymphoblastic Leukemia, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT07153796 is a Phase 2 study of B-cell Acute Lymphoblastic Leukemia that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 60 participants, below the 86-participant average among 21 other B-cell Acute Lymphoblastic Leukemia trials with a reported enrollment target (30% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07153796, a Phase 2 study of B-cell Acute Lymphoblastic Leukemia, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single arm open-label phase 2 trial to study the safety and efficacy of SC Blinatumomab in combination with low-intensity chemotherapy for older or unfit patients with B-ALL.
Conditions Studied
Interventions
- DRUG Blinatumomab
- DRUG Mini-CVD
- DRUG MTX/ARA-C
Study Locations (1)
Texas
- The University of Texas M. D. Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-01-30 |
| Est. Completion | 2033-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07153796
The ClinicalTrials.gov registry entry for NCT07153796 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 86-participant average among 21 other B-cell Acute Lymphoblastic Leukemia trials with a reported enrollment target (30% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with B-cell Acute Lymphoblastic Leukemia appearing as the primary indexed condition, and to 3 interventions - of which Blinatumomab is the first listed.
NCT07153796 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT07153796 about?
NCT07153796 is a clinical study titled "A Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-cell Acute Lymphoblastic Leukemia". This is a single arm open-label phase 2 trial to study the safety and efficacy of SC Blinatumomab in combination with low-intensity chemotherapy for older or unfit patients with B-ALL.
What is the current status of trial NCT07153796?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2026-01-30. Estimated completion is 2033-09-30.
What conditions does trial NCT07153796 study?
This clinical trial studies the following conditions: B-cell Acute Lymphoblastic Leukemia.
What interventions are being tested in trial NCT07153796?
The interventions under investigation include: Blinatumomab (DRUG), Mini-CVD (DRUG), MTX/ARA-C (DRUG).
Who is sponsoring clinical trial NCT07153796?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07153796 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for B-cell Acute Lymphoblastic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT
RECRUITING · Phase 2
-
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
RECRUITING · Phase 2
-
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
RECRUITING · Phase 2
-
A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL)
ACTIVE NOT RECRUITING · Phase 2
-
Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients
ACTIVE NOT RECRUITING · Phase 2
-
Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.